Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | FLT4 | P35916 | 2/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 7/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781447 | 0.85 | QDPR (0.56) | ALKPDE4BFLT4PTK2EGFR | |
| SCHEMBL1781826 | 0.84 | HTR2C (0.47) | ALKHTR2CPDE4BEGFRCAMK2D | |
| SCHEMBL3315978 | 0.83 | PDE4B (0.59) | ALKPDE4BQDPR | |
| SCHEMBL12479659 | 0.83 | PDE4B (0.51) | ALKPDE4BQDPR | |
| SCHEMBL27933804 | 0.82 | PDE4B (0.45) | ALKPDE4BEGFRQDPRPIK3CD | |
| SCHEMBL26796777 | 0.81 | ALDH1A1 (0.43) | PDE4B | |
| SCHEMBL17197372 | 0.81 | MEN1 (0.53) | PDE4BEGFRQDPR | |
| SCHEMBL3314367 | 0.81 | PDE4B (0.43) | PDE4BEGFRPIK3CDABL1KDR | |
| SCHEMBL3006555 | 0.80 | NAMPT (0.52) | — | |
| SCHEMBL17197329 | 0.79 | EGFR (0.48) | ALKPDE4BEGFRCAMK2DCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015158310-A1 | TYROSINE KINASE INHIBITOR AND USES THEREOF | 山东轩竹医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | ALK 15/4885HTR2C 3500/4885PDE4B 1979/4885 |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | ALK 2828/4885HTR2C 4708/4885PDE4B 4299/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | ALK 15/4885HTR2C 3500/4885PDE4B 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.